Hemington Wealth Management Purchases 404 Shares of ARK Genomic Revolution ETF (BATS:ARKG)

Hemington Wealth Management boosted its position in shares of ARK Genomic Revolution ETF (BATS:ARKG) by 44.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,310 shares of the company’s stock after buying an additional 404 shares during the period. Hemington Wealth Management’s holdings in ARK Genomic Revolution ETF were worth $30,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ARKG. Sanctuary Advisors LLC bought a new position in ARK Genomic Revolution ETF during the second quarter valued at approximately $222,000. Summit Investment Advisory Services LLC bought a new position in ARK Genomic Revolution ETF during the third quarter valued at approximately $417,000. Crescent Grove Advisors LLC lifted its stake in shares of ARK Genomic Revolution ETF by 1.6% in the 3rd quarter. Crescent Grove Advisors LLC now owns 28,914 shares of the company’s stock valued at $740,000 after purchasing an additional 460 shares during the last quarter. Prospera Financial Services Inc lifted its stake in shares of ARK Genomic Revolution ETF by 18.2% in the 3rd quarter. Prospera Financial Services Inc now owns 33,607 shares of the company’s stock valued at $860,000 after purchasing an additional 5,180 shares during the last quarter. Finally, Captrust Financial Advisors bought a new stake in shares of ARK Genomic Revolution ETF in the 3rd quarter valued at approximately $485,000.

ARK Genomic Revolution ETF Price Performance

BATS:ARKG opened at $27.67 on Friday. The company has a 50-day moving average of $25.48 and a 200 day moving average of $25.24.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.